-
phaware post and email announcement
phaware post and email announcement
Opportunity for Tyvaso users (Sponsored)
United Therapeutics is conducting the BREEZE Study which is investigating a way to deliver the same medication (treprostinil) that you know as Tyvaso with a much smaller device. This involves combining a dry powdered form of treprostinil (TreT) with a small, portable dry powder inhaler.
The BREEZE Study is looking for patients with PAH on a stable dose of Tyvaso (6 to 12 breaths 4 times daily) who will be evaluated after switching to a corresponding dose of TreT. Participants who complete 3-weeks of treatment with TreT will be given the opportunity to continue using it.
The purpose of this research study is to investigate the safety and how well TreT is tolerated in participants with PAH currently treated with Tyvaso.
If you’re interested in learning more about this study, please refer to NCT03950739 on ClinicalTrials.gov and/or contact Jason Scoggin at [email protected] or 919-425-5304.
-
0 Replies
Sorry, there were no replies found.
Log in to reply.